H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $13 from $15 and keeps a Buy rating on the shares. The firm cites share dilution from the most recent equity raise for the target cut.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Announces $135M Public Offering
- Lexeo Therapeutics price target lowered to $18 from $20 at Leerink
- Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
- Lexeo announces common stock and warrants offering, no amount given
- 3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts